PALO ALTO, Calif., April 27 /PRNewswire-FirstCall/ -- Telik, Inc. announced that its quarterly conference call and webcast will be held on Thursday, May 4, 2006 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). The call will follow the release of Telik’s financial results for the first quarter ended March 31, 2006 earlier that day.
The conference call will be accessible via Telik’s website at www.telik.com or by telephone at 877-209-0397 or 612-332-1213. An archive of the conference call will be available on the Telik website from approximately 8:30 p.m. Eastern time on May 4 through May 11, 2006, or by telephone at 800-475-6701 or 320-365-3844, access code 827658.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA(R) (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, Inc., +1-650-845-7728, or cdeguzman@telik.com
Web site: http://www.telik.com//
